Jun Zhu

Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy

He Huang, Xueying Li, Jun Zhu et al. · JAMA · 2014 · 229 citations

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 152 citations · Full text

Lymphoid Neoplasia, End-of-induction Pet Response, Medicine +7

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252

Shu Zhang, Jie Cheng, Chenlian Quan et al. · Molecular Therapy — Nucleic Acids · 2019 · 127 citations · Full text

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group

Seok Jin Kim, Chiun Hsu, Yu-Qin Song et al. · European Journal of Cancer · 2013 · 121 citations · Full text

Lymphoid Neoplasia, Hepatology, B-cell Lymphoma Patients +5